Literature DB >> 30053318

Can Neutrophil-to-Lymphocyte Ratio, Monocyte-to-Lymphocyte Ratio, and Platelet-to-Lymphocyte Ratio at Day +100 be used as a prognostic marker in Multiple Myeloma patients with autologous transplantation?

Serife Solmaz Medeni1, Celal Acar1, Aybuke Olgun2, Alev Acar2, Ahmet Seyhanlı2, Emin Taskıran2, Omur Gokmen Sevindik3, Inci Alacacıoglu2, Ozden Piskin2, Mehmet Ali Ozcan2, Fatih Demirkan2, Bulent Undar2, Guner Hayri Ozsan2.   

Abstract

BACKGROUND: Recent reports have showed that neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR) are predictors of progression-free survival (PFS) and overall survival (OS) in many types of cancer. This study evaluates the predictive value of NLR, MLR, and PLR for survival in MM patients treated with to ASCT.
METHODS: A set of data consisting of 150 patients who underwent autologous stem cell transplantation (ASCT) for MM was collected retrospectively. The prognostic value of NLR, MLR, and PLR was investigated with Kaplan-Meier method.
RESULTS: The prognostic value of NLR, MLR, and PLR was analyzed by a receiver operating characteristic (ROC) curve established to determine the cutoff. These cutoff values of NLR, PLR, and MLR were found 1.46, 86, and 0.27, respectively, on the 100th day of post-transplantation period. The overall survival (OS) and the post-transplantation OS of the patients with high NLR, MLR, and PLR levels on the 100th day of post-transplantation were shorter than the other group (P = 0.05, P = 0.018 [NLR], P = 0.05, P = 0.002 [MLR], P = 0.000, P = 0.001 [PLR]). The post-transplantation progression-free survival (PFS) of the patients with high NLR, MLR, and PLR levels on the 100th day of post-transplantation was shorter as well (P = 0.036, P = 0.001, P = 0.001, respectively).
CONCLUSION: As increased NLR, MLR, and PLR predicted poor clinical outcome in MM patients with autologous transplantation in this study, they may serve as cost-effective and rapidly available prognostic biomarkers for these patients.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Monocyte Lymphocyte Ratio (MLR); Multiple myeloma; Neutrophil-to-Lymphocyte Ratio (NLR); Platelet-to-Lymphocyte Ratio (PLR)

Mesh:

Substances:

Year:  2018        PMID: 30053318     DOI: 10.1111/ctr.13359

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  9 in total

1.  Prognostic Impact of Indicators of Systemic Inflammation and the Nutritional Status of Patients with Resected Carcinoma of the Ampulla of Vater: A Single-Center Retrospective Study.

Authors:  Yuji Shimizu; Ryo Ashida; Teiichi Sugiura; Yukiyasu Okamura; Takaaki Ito; Yusuke Yamamoto; Katsuhisa Ohgi; Shimpei Otsuka; Akifumi Notsu; Katsuhiko Uesaka
Journal:  World J Surg       Date:  2021-10-18       Impact factor: 3.352

2.  Significance of preoperative peripheral blood neutrophil-lymphocyte ratio in predicting postoperative survival in patients with multiple myeloma bone disease.

Authors:  Zi-Yu Xu; Xing-Chen Yao; Xiang-Jun Shi; Xin-Ru Du
Journal:  World J Clin Cases       Date:  2022-05-16       Impact factor: 1.534

3.  Clinical significance of systemic immune-inflammation index (SII) and C-reactive protein-to-albumin ratio (CAR) in patients with esophageal cancer: a meta-analysis.

Authors:  Yi Zhang; Guoliang Xiao; Rong Wang
Journal:  Cancer Manag Res       Date:  2019-05-07       Impact factor: 3.989

4.  Predictive role of monocyte-to-lymphocyte ratio in patients with Klebsiella pneumonia infection: A single-center experience.

Authors:  Jia-Lu Wang; Xiao-Ye Lu; Xin-Hui Xu; Ke-Ji Zhang; Hao Gong; Dan Lv; Zhu-Ang Ni; Chang-Qing Zhu
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

5.  High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling.

Authors:  A Romano; N L Parrinello; V Simeon; F Puglisi; P La Cava; C Bellofiore; C Giallongo; G Camiolo; F D'Auria; V Grieco; F Larocca; A Barbato; D Cambria; E La Spina; D Tibullo; G A Palumbo; C Conticello; P Musto; F Di Raimondo
Journal:  Sci Rep       Date:  2020-02-06       Impact factor: 4.379

6.  Are the Derived Indexes of Peripheral Whole Blood Cell Counts (NLR, PLR, LMR/MLR) Clinically Significant Prognostic Biomarkers in Multiple Myeloma? A Systematic Review And Meta-Analysis.

Authors:  Xinwen Zhang; Jialin Duan; Zhenyu Wen; Hao Xiong; Xiaomin Chen; Yang Liu; Kunyu Liao; Chunlan Huang
Journal:  Front Oncol       Date:  2021-11-23       Impact factor: 6.244

Review 7.  Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities.

Authors:  Cirino Botta; Francesco Mendicino; Enrica Antonia Martino; Ernesto Vigna; Domenica Ronchetti; Pierpaolo Correale; Fortunato Morabito; Antonino Neri; Massimo Gentile
Journal:  Cancers (Basel)       Date:  2021-06-28       Impact factor: 6.639

Review 8.  Predictive Role of Immune Profiling for Survival of Multiple Myeloma Patients.

Authors:  Liu Zhaoyun; Fu Rong
Journal:  Front Immunol       Date:  2021-07-05       Impact factor: 7.561

Review 9.  Actors on the Scene: Immune Cells in the Myeloma Niche.

Authors:  Patrizia Leone; Antonio Giovanni Solimando; Eleonora Malerba; Rossella Fasano; Alessio Buonavoglia; Fabrizio Pappagallo; Valli De Re; Antonella Argentiero; Nicola Silvestris; Angelo Vacca; Vito Racanelli
Journal:  Front Oncol       Date:  2020-10-29       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.